

Indices	Value	Pts	Chg (%)
SENSEX	31702.25	(189.98)	(0.60)
NIFTY	9912.85	(61.55)	(0.62)
SGX NIFTY*	9872.00	(9.00)	(9.00)
DOW Jones	21987.56	39.46	0.18
S&P 500	2476.55	4.90	0.20
Nasdaq	6435.33	6.67	0.10
FTSE	7411.47	(40.43)	(0.54)
CAC	5103.97	(19.29)	(0.38)
DAX	12102.21	(40.43)	(0.33)
Shanghai Composite*	3386.19	6.61	0.20
Nikkei*	19407.50	(100.75)	(0.52)
Hang Seng*	27792.00	51.74	0.19

*As at 8.30 am

Most Active Call & Put Symbol	Strike Price	OI	Chg (%)
NIFTY	10000 CE	3507600	22.63
NIFTY	9800 PE	3531900	39.54

Commodity	Value	Pts	Chg (%)
NYMEX Crude (USD)	47.41	+0.12	0.25
Brent Crude (USD)	52.14	(0.20)	(0.38)
Gold (INR)	30105	282.00	0.95
Silver (INR)	41421	1400.00	3.50
Copper (INR)	448	6.25	1.41
Zinc (INR)	205	0.35	0.17
Cotton (INR)	18840	80.00	0.43

Currency	Value	Pts	Chg (%)
USD/Rupee	64.12	0.07	0.11
Euro/Rupee	76.34	0.17	0.22
Pound/Rupee	82.91	0.11	0.13
Euro /USD	1.19	0.00	0.08
Dollar Index	92.51	(0.13)	(0.14)

Volatility	Value	Pts	Chg (%)
CBOE VIX	10.13	(0.46)	(4.34)
India VIX	13.16	1.48	12.67

Interest Rates	Value	Bps change
India 10-Yr Yield	6.50%	+1
US 10-Yr Yield	2.13%	(3)

Trade Statistics	BSE	NSE	F & O
Turnover (INR Crs)	3396.73	24830.67	469922.27
Advance (Nos)	972 (34%)	582 (34%)	NA
Declines (Nos)	1682 (58%)	1124 (58%)	NA
Unchanged	222 (8%)	82 (8%)	NA

Market Summary

The market ended on a negative note on Monday. The market breadth was negative with more than 5 losers for every 3 gainers on BSE. 972 shares advanced whereas 1682 shares declined and 222 shares were unchanged on BSE.

BSE Sensex plunged 190 points or (0.6%) to close at 31702. Nifty 50 was down 62 points or (0.6%) to settle at 9913. BSE Mid-Cap index was down 4 points or (0.0%) to settle at 15502. BSE Small-Cap index gained 30 points or (0.2%) to settle at 15898.

Top gainer in BSE Sensex were Coal India (3.4%), Sun Pharma (2.8%), ONGC (1.1%), BHEL (0.7%) and Lupin (0.2%) whereas top loser in BSE were Adani Ports (2.6%), Infosys (2.0%), Hero motocorp (1.8%), Tata Motors (1.6%) and Bharti Airtel (1.6%).

US markets closed.

European markets closed negative, FTSE declined 40 points (0.5%) to close at 7411, CAC was down 19 points (0.4%) to close at 5104 and DAX lost 40 points (0.3%) to close at 12102.

Macro News

- The INR 200 bn plywood, plyboard, medium density fibreboard and particle-board industry is hopeful of reduction in GST rate to 18% from the current 28% in the forthcoming council meeting. Several ministers with whom board members have interacted had assured to look into their plight and they hope the favourable decision in the forthcoming GST council meeting on September 9 at Hyderabad.
- Housing finance companies (HFCs) are likely to need around INR 90-160 bn of external capital (11-19% of their existing net worth) over the next three year to grow at 20-22%, said a report by rating agency ICRA. Most of this incremental capital requirement would be for the small HFCs, including those operating in affordable housing space.
- Petroleum Minister Dharmendra Pradhan on said the dynamic pricing regime, whereby prices of transport fuels are revised daily, would continue despite petrol prices going up by over INR 6 per litre since the scheme was introduced pan-India from mid-June. Since daily revision was implemented on 16th June, petrol prices have increased by Rs 6.60 to reach Rs 69.66 a litre in Delhi, while that of diesel have risen by Rs 4.02 to Rs 57.38..

Institutional Activity	04-Sep	Cash Sep2017
FII (INR Crs)		
Buy	2203	5356
Sell	3077	7063
Net	(874)	(1707)
DII (INR Crs)		
Buy	1883	4706
Sell	1932	4024
Net	(49)	683

FII Derivative Statistics (NSE)				
Particulars	Buy (INR Crs)	Sell (INR Crs)	OI (Nos)	Chg (%)
INDEX FUTURES	1191.97	1661.54	176107	10.00
INDEX OPTIONS	49827.10	48827.86	840255	2.75
STOCK FUTURES	8182.00	7967.92	743218	1.14
STOCK OPTIONS	5203.66	5165.65	39031	24.05
Total	64404.73	63622.97		

Gainers & Losers	Price	Chg (%)
Gainers (INR)		
Coal India	246.40	3.38
Sun Pharma	500.55	2.79
ONGC	161.60	1.06
BHEL	130.95	0.69
Lupin	995.90	0.24
Losers (INR)		
Adani Ports	384.30	(2.60)
Infosys	901.30	(2.04)
Hero Motocorp	3973.60	(1.82)
Tata Motors	384.40	(1.61)
Bharti Airtel	415.85	(1.56)

Sectoral Performance	Value	Pts	Chg (%)
S&P BSE Small Cap	15897.98	30.24	0.19
S&P BSE Mid-Cap	15502.12	(3.72)	(0.02)
S&P BSE Auto	23605.32	2.54	0.01
S&P BSE BANKEX	27402.06	(73.62)	(0.27)
S&P BSE Capital Goods	17356.74	85.44	0.49
S&P BSE FMCG	10113.55	(28.66)	(0.28)
S&P BSE Healthcare	13171.90	(39.47)	(0.30)
S&P BSE IT	10019.75	(42.40)	(0.42)
S&P BSE Metals	13248.33	(44.56)	(0.34)
S&P Oil & Gas	15183.76	90.11	0.60

Key News

ONGC to raise its first ever debt of Rs 25,000 cr to fund HPCL buy

Cash rich ONGC will raise its first debt ever, of INR 250 bn, to part fund the INR 370 bn acquisition of government's stake HPCL. ONGC has about INR 130 bn in cash and would need to borrow the rest to fund the buying of government's 51.11% stake in HPCL. ONGC has sought shareholder approval for "borrowing/ raising funds in Indian rupee and/ or foreign currency by issue of debt instruments. The resolution would come up for voting at the company's AGM of shareholders on September 27.

In relief to over 30,000 homebuyers, SC stays Jaypee insolvency proceedings

The Supreme Court has stayed the National Company Law Tribunal's (NCLT's) order initiating insolvency proceedings against Noida-based Jaypee Infratech. The decision comes as a relief to over 30,000 homebuyers whose position became ambiguous after the August 9 NCLT order as their status was unclear under the Insolvency and Bankruptcy code. Though the regulator issued a new form, it was not clear where the homebuyers would stand in the waterfall of payments.

Lupin launches generic Fosrenol Chewable Tablets in US

Ajanta Pharma has received final approval from the US health regulator for Entacapone tablets, used in the treatment of Parkinson's disease. It is a bioequivalent generic version of Comtan tablets. The company said it will launch the product shortly in the strength of 200mg tablets. This new approval is part of portfolio of products that the company has developed for the US market. Ajanta Pharma has 35 ANDAs of which it has final approval for 20 ANDAs, tentative approval for 2 ANDA and 13 ANDAs are under review with USFDA.

International Data

Country	Data	Forecast	Previous
UK	Services PMI	53.5	53.8
US	FOMC Member Brainard Speaks	NA	NA

Sharad Avasthi

Head - Equity Research

sharad.avasthi@spagroupindia.com

Tel.: +91-022-42895600

Ext.206

Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPA Securities is a SEBI registered securities broking company having membership of NSE, BSE & MCX for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. www.spasecurities.com.

SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

General Disclosures: This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act.1956, through SPA Securities nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited.

The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at www.nseindia.com and <http://economicstimes.indiatimes.com/markets/stocks/stock-quotes>. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes

Statements on ownership and material conflicts of interest, compensation - SPA and Associates

Disclosure of interest statement	Yes/No
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
• Managing/co-managing public offering of securities	
• Investment banking/merchant banking/brokerage services	No
• products or services other than those above	
• in connection with research report	
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company;	No

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

For More Information Visit Us At : www.spasecurities.com

SPA CAPITAL SERVICES LIMITED

Investment Advisory services,
AMFI Reg. No. ARN-007

SPA Capital Advisors Limited

SEBI registered Category-1
Merchant Bankers
SEBI Regn. No. INM000010825

SPA COMTRADE PRIVATE LIMITED

SPA INSURANCE BROKING SERVICES LTD.

Direct Broker for Life and General
Insurance Broking
IRDA Lic. Code No. DB053/03

SPA Securities Ltd

NSE Cash
NSE Future & Option
NSE Currency Derivatives
BSE Cash
BSE Currency Derivatives
MCX-SX Cash
MCX-SX Future & Option
MCX-SX Currency Derivatives
Mutual Fund
CDSL DP
NSDL DP
SEBI Research Analyst

SEBI Reg. Nos.

INB231178238
INF231173238
INE231178238
INB011178234
INE011178234
INB261178231
INF261178231
INE261178238
ARN 77388
IN-DP-CDSL-485-2008
IN-DP-NSDL-316-2009
INH100002615